FDA’s Candid Overview Of Cosmetics Regime Signals Support For Reform Bill
This article was originally published in The Rose Sheet
Executive Summary
In a letter to California Democratic Senator Dianne Feinstein, FDA’s Acting Associate Commissioner for Legislation Dayle Cristinzio acknowledges the agency’s limited insight into cosmetic formulations and safety information, which makes it a struggle to respond to issues as they arise. Feinstein characterizes the letter as an admission of current system failings and a nod of support for her Personal Care Products Safety Act.